Selective HLA Class II Allele-Restricted Activation of Atabecestat Metabolite-Specific Human T-Cells. (2024)
Attributed to:
A personalised approach to manage adverse reactions to CFTR modulator therapy in patients with cystic fibrosis
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1021/acs.chemrestox.4c00262
PubMed Identifier: 39348529
Publication URI: http://europepmc.org/abstract/MED/39348529
Type: Journal Article/Review
Volume: 37
Parent Publication: Chemical research in toxicology
Issue: 10
ISSN: 0893-228X